Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy.

Science advances·2026

Same author

Surface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis.

Nature communications·2026

Same author

A nano-system combines mitochondrial damage with microtubule stabilization for cancer metastasis suppression.

Journal of materials chemistry. B·2025

Same author

Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics.

ACS nano·2025

Same author

Enhance Efferocytosis and Block the Macrophages-Platelets Feedback Loop for Targeted Treatment of Psoriasis.

ACS nano·2025

Same author

Advances in Oral Biomacromolecule Therapies for Metabolic Diseases.

Pharmaceutics·2025

Search research articles

Related Experiment Video

Updated: Mar 9, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Subcellular co-delivery of two different site-oriented payloads for tumor therapy.

Qingqing Yang¹, Lei Wu¹, Lian Li¹

¹Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, P.R. China. huangyuan0@163.com.

|January 10, 2017

Summary

This study introduces a smart nanocarrier for dual-drug cancer therapy, improving subcellular delivery and enhancing tumor inhibition with reduced toxicity. The novel platform targets two agents to specific sites for superior anti-cancer effects.

More Related Videos

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Experiment Videos

Last Updated: Mar 9, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Area of Science:

Biomedical Engineering
Nanotechnology
Cancer Therapy

Background:

Co-delivery of multiple agents via nanocarriers is crucial for cancer therapy.
Achieving targeted subcellular delivery of multiple drugs remains a significant challenge.

Purpose of the Study:

To develop a smart nanovehicle for effective co-delivery of two distinct anti-cancer agents.
To achieve site-specific organelle targeting using stimulus-responsive release and nucleus-targeted modification.

Main Methods:

Loading all trans retinoic acid (RA)-conjugated camptothecin (RA-CPT) into a polyhedral oligomeric silsesquioxane (POSS)-based core.
Grafting docetaxel (DTX) onto N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers and self-assembling into micelles with the POSS core.
Evaluating drug release, cellular uptake, cytotoxicity, DNA damage, apoptosis induction, and in vivo tumor inhibition.

Main Results:

The dual-drug nanomicelles demonstrated environment-responsive drug release.
Nucleus-targeted RA significantly enhanced the nuclear transport of CPT, leading to superior synergistic cytotoxicity.
The platform showed enhanced DNA damage and apoptosis induction compared to single-drug systems.
In vivo studies revealed significantly improved tumor inhibition (87.1%) and reduced systemic toxicity.

Conclusions:

The developed nanocarrier platform enables effective "one platform, two targets" combinatory anti-cancer therapy.
Stimulus-responsive release and nucleus-targeted modification are key to enhanced therapeutic efficacy.
This strategy offers a promising approach for improving cancer treatment outcomes.